Humanized Immune Checkpoint Inhibitor Mouse Models

Evaluate your human specific immunotherapy In Vivo

Humanized checkpoint inhibitor mice provide a unique opportunity to study the effect of human specific immunotherapies in vivo. By genetically engineering the mouse models to have human immune targets, these models are able to provide a higher degree of accuracy in terms of predicting drug efficacy. Compared to other animal models, humanized checkpoint inhibitor mice are ideal for testing the effect of your treatment candidate because they can respond to immunotherapy treatments in the same way humans do.

humanized-mouse-models-1

Benefits of using humanized immune checkpoint inhibitors for I/O research

  • Enable the evaluation of human-specific biological therapies in vivo faster than traditional animal models
  • Double and triple KI models
  • Lack of expression of the murine target gene, avoiding cross-reactivity
  • Provides a more predictive model for how drugs will perform in the clinic

humanized-mouse-models-charts-1

Learn more about our humanized immune checkpoint models.

Contact our experts to help advance your immunotherapy candidate with our trusted preclinical research services.

Available Models

Single Target Double Target Triple Target
hACE2 hTREM2 hCD47/hSIRPα hFcgRs/hCD47/hSIRPα
hCD3E hCD22 hPD1/hLAG3 hPD1/hPDL1/hCD137
hHRAS hCTLA4 hPD1/hBTLA hPD1/hPDL1/hCD40
hPD1 hLAG3 hPD1/hOX40 hPD1/hPDL1/hCD73
hTIM3 hSIRPα hPD1/hCD137 hPD1/hPDL1/hLAG3
hBTLA hVISTA hPD1/hPDL1 hPD1/hPDL1/hOX40
hCD3EDG hCD27 hPD1/hCD47 hPD1/hPDL1/hSIRPα
hIFNAR1 hDPP4 hPD1/hSIRPα hPD1/hPDL1/hTIGIT
hPDL1 hLLRC32 hPD1/hCSF1R hPD1/hPDL1/hTIM3
hTMPRSS2 hSTING1 hPD1/hTIGIT hPD1/hPDL1hCTLA4
hCCN1 hVTCN1 hPD1/hCTLA4  
hCD47 hCD28 hPD1/hTIM3  
hIL12RB1 hFcgRs hPD1/hGITR  
hPVRIG hOX40 hPDL1/hB7H3  
hTNFR2 hTIGIT    
hCD137 hCD38    
hCD73 hFcRn    
hIL12RB2 hRANK    
hSIGLEC15      

Immuno-Oncology

Immuno-oncology

Comprehensive preclinical services for immuno-oncology.

TD2’s extensive knowledge of CAR-T in both solid and hematologic tumors enables rapid evaluation of your CAR-T cell therapy, moving your therapeutic program forward to the clinic.

Large panel of human and murine tumor models

Cell therapy models


  • 8 years of experience in cell therapy
  • Expertise includes: CAR-T, NK-CAR, IPS-NKs, Macrophages

Syngeneic mouse models


  • Fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors

GET STARTED

TD2 navigates the complexities of drug discovery to guide you down a smarter path for earlier, more complete results.

Contact us today to learn more about our ADME and biomarker offerings and how we can set your treatment up for success from the start.